ARTINI HLDG (00789) Signs Strategic Partnership Agreement with Baiyunshan Weiy for Joint R&D in Health Industry and Market Expansion

Stock News
09/19

ARTINI HLDG (00789) announced that on September 19, 2025, the company signed a strategic cooperation agreement with Guangzhou Baiyunshan Weiy Industrial Co., Ltd. (Baiyunshan Weiy) to jointly develop products in the health industry and expand markets through strategic cooperation. The cooperation period is one year.

Baiyunshan Weiy is one of the subsidiaries under Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, which is listed on both the Shanghai Stock Exchange (600332.SH) and the Main Board of The Stock Exchange of Hong Kong Limited (00874), focusing on the health industry.

According to the cooperation agreement, the proposed strategic cooperation between the Group and Baiyunshan Weiy mainly includes the following areas:

1. Joint Product Development: Both parties will jointly develop innovative products in the health industry, including natural plant extracts, functional health products, and personal care products.

2. Market Expansion: Both parties plan to bring cooperatively developed products and related existing products to overseas markets. Baiyunshan Weiy will provide brand marketing support to the Group, including brand strategy, brand tactics, trademark licensing, and other support. It will also provide the Group with technical consultation, product promotion, and marketing guidance services related to health product sales and market promotion.

The Group has been actively expanding its beauty and health product sales business in recent years. This strategic cooperation with Baiyunshan Weiy aligns with the Group's business development strategy and long-term positioning in the health industry.

The Board of Directors believes that this strategic cooperation can combine the Group's advantages in international markets and sales platforms with Baiyunshan Weiy's technological, brand, and product advantages to achieve synergistic effects. This initiative is expected to enrich the Group's product portfolio, enhance core competitiveness in the health industry, and open new revenue sources. Therefore, the Board considers that signing the cooperation agreement with Baiyunshan Weiy is in the overall interests of the Company and its shareholders.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10